Virax Biolabs Group Limited [NASDAQ: VRAX] stock went on an upward path that rose over 6.00% on Monday, amounting to a one-week price increase of more than 3.06%. The company report on September 1, 2023 at 7:30 AM that Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum.
Virax Biolabs Group Limited (“Virax” or the “Company”) (Nasdaq: VRAX), an innovative diagnostics company focused on the detection of immune responses and diagnosis of viral diseases, announced today the appointment of Dr. Nigel McCracken as the Company’s Chief Operating Officer (“COO”). Dr. McCracken will succeed Mr. Cameron Shaw, who is moving to Virax’s Advisory Board, and will lead the Company’s various growth initiatives, including the Company’s expected near-term research-use-only launch of ViraxImmune™.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
“We are excited to welcome Dr. McCracken to our executive team,” commented Mr. James Foster, Chairman of the Board and Chief Executive Officer of Virax. “With over 10 years of experience in diagnostics and deep experience in various operational roles, including overseeing the optimization and rollout of products from preclinical to commercial stage at multinational healthcare companies including Abbott Laboratories, Nigel is well equipped to execute on our growth initiatives for ViraxImmune™.” Mr. Foster continued, “On behalf of the executive leadership team and the board of directors, I would like to thank Mr. Shaw for his innumerable contributions to Virax Biolabs and his unwavering commitment to our overall mission.”.
Over the last 12 months, VRAX stock dropped by -88.86%. The one-year Virax Biolabs Group Limited stock forecast points to a potential upside of 81.5.
The market cap for the stock reached $6.64 million, with 17.89 million shares outstanding and 11.56 million shares in the current float. Compared to the average trading volume of 196.96K shares, VRAX stock reached a trading volume of 5003584 in the most recent trading day, which is why market watchdogs consider the stock to be active.
VRAX Stock Performance Analysis:
Virax Biolabs Group Limited [VRAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.06. With this latest performance, VRAX shares dropped by -5.41% in over the last four-week period, additionally sinking by -57.82% over the last 6 months – not to mention a drop of -88.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VRAX stock in for the last two-week period is set at 50.34, with the RSI for the last a single of trading hit 53.41, and the three-weeks RSI is set at 48.77 for Virax Biolabs Group Limited [VRAX]. The present Moving Average for the last 50 days of trading for this stock 0.3828, while it was recorded at 0.3583 for the last single week of trading, and 0.6090 for the last 200 days.
Insight into Virax Biolabs Group Limited Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Virax Biolabs Group Limited [VRAX] shares currently have an operating margin of -66963.68 and a Gross Margin at -15.94. Virax Biolabs Group Limited’s Net Margin is presently recorded at -63748.32.
Return on Total Capital for VRAX is now -145.92, given the latest momentum, and Return on Invested Capital for the company is -133.90. Return on Equity for this stock declined to -133.90, with Return on Assets sitting at -110.69. When it comes to the capital structure of this company, Virax Biolabs Group Limited [VRAX] has a Total Debt to Total Equity ratio set at 1.60. Additionally, VRAX Total Debt to Total Capital is recorded at 1.58, with Total Debt to Total Assets ending up at 1.49.
Reflecting on the efficiency of the workforce at the company, Virax Biolabs Group Limited [VRAX] managed to generate an average of -$496,136 per employee.
Virax Biolabs Group Limited [VRAX] Institutonal Ownership Details
The top three institutional holders of VRAX stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in VRAX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in VRAX stock with ownership which is approximately 5.7381%.
